NEWARK BETH ISRAEL MEDICAL CENTER
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1900-01-01
- Employees
- -
- Market Cap
- -
Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab
Not yet recruiting
- Conditions
- Hemophilia A
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Newark Beth Israel Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT06104826
- Locations
- ๐บ๐ธ
Newark Beth Israel Medical Center, Newark, New Jersey, United States
SPG Block for Acute Pediatric Migraine
Phase 3
- Conditions
- Sphenopalatine NeuralgiaMigraine in ChildrenMigraine in Adolescence
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Newark Beth Israel Medical Center
- Target Recruit Count
- 72
- Registration Number
- NCT03984045
- Locations
- ๐บ๐ธ
Newark Beth Israel Medical Center, Newark, New Jersey, United States
Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?
Phase 4
Completed
- Conditions
- Sickle Cell Anemia Crisis
- Interventions
- Drug: Normal saline
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Newark Beth Israel Medical Center
- Target Recruit Count
- 71
- Registration Number
- NCT03541980
- Locations
- ๐บ๐ธ
Newark Beth Israel, Newark, New York, United States
Once-a-day Tacrolimus Conversion Study: The OneTAC Trial
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- Newark Beth Israel Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT02545972
- Locations
- ๐บ๐ธ
Newark Beth Israel Medical Center, Newark, New Jersey, United States
Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome
Phase 4
- Conditions
- SmokingAcute Coronary Syndrome
- Interventions
- Drug: control
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2010-07-27
- Lead Sponsor
- Newark Beth Israel Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT01170338
- Locations
- ๐บ๐ธ
Newark Beth Israel Medical Center, Newark, New Jersey, United States
Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2015-05-28
- Lead Sponsor
- Newark Beth Israel Medical Center
- Target Recruit Count
- 150
- Registration Number
- NCT00299221
- Locations
- ๐บ๐ธ
Newark Beth Israel Medical Center, Newark, New Jersey, United States
๐บ๐ธMt. Sinai Cardiovascular Institute, New York, New York, United States